Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-08-23 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details a specific corporate event: Janssen submitting an application to the EMA to broaden the label for daratumumab, which triggers milestone payments to Genmab. This is a material corporate update concerning drug development, regulatory submissions, and financial milestones related to a licensed product. It is not a full financial report (10-K or IR), an earnings release (ER), a management discussion (MDA), or a formal proxy/voting document. Since it is a specific announcement of a corporate event/development that doesn't fit the highly specific categories like DIRS, DIV, or CAP, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for company announcements not covered elsewhere, or potentially a general 'LTR' if viewed as a regulatory update, but RNS is the best fit for a general press release style announcement of this nature.
2016-08-23 English
Regulatory Filings 2016
Regulatory Filings Classification · 100% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and details a specific corporate event: Janssen submitting an application to the EMA regarding an expansion of the indication area for daratumumab, which triggers a milestone payment to Genmab. This type of announcement, which communicates a specific, material business event (regulatory filing submission and associated financial impact) but is not a full financial report (like 10-K or IR) or a transcript, fits best under the general category for regulatory/corporate news releases that aren't covered by more specific codes like DIV, DIRS, or MANG. Since it is a formal announcement of a significant corporate/regulatory action, and it is not a full financial report, the most appropriate classification among the provided options is RNS (Regulatory Filings), which serves as a general regulatory announcement fallback. The length (11,105 chars) suggests it is a substantive announcement, not just a brief notice of publication (RPA).
2016-08-23 Danish
Genmab meddeler, at der er indsendt registreringsansøgning i Europa for daratumumab til behandling af recidiverende myelomatose
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Genmab regarding a regulatory filing submission (marketing authorization application) for their drug daratumumab to the European Medicines Agency (EMA). It details the clinical trial data supporting the application and the financial implications (milestone payments). As it is a specific regulatory announcement regarding company operations and product development, it falls under the 'Regulatory Filings' category, as it does not fit into specific categories like M&A, Earnings Release, or Annual Reports.
2016-08-23 English
Genmab meddeler, at der er indsendt registreringsansøgning i Europa for daratumumab til behandling af recidiverende myelomatose
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' (No. 38) from Genmab regarding a regulatory submission for a drug (daratumumab) to the EMA. It provides details on the submission, the clinical studies involved, and the financial impact (milestone payments). It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it contains substantive news content. Therefore, it is classified as a general regulatory announcement.
2016-08-23 English
Director's Dealing 2016
Director's Dealing Classification · 99% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and explicitly references compliance with Article 19 of Regulation No 596/2014 (MAR - Market Abuse Regulation). It details transactions (specifically 'Salg af aktier' - Sale of shares) conducted by individuals holding management responsibilities ('President & Chief Executive Officer', 'Executive Vice President & Chief Financial Officer', 'Bestyrelsesmedlem' - Board Member) in the company's shares. This type of mandatory disclosure regarding insider transactions by management/board members falls directly under the definition of Director's Dealing (insider trades). The corresponding code is DIRS.
2016-08-18 English
Regulatory Filings 2016
Regulatory Filings
2016-08-18 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.